Teva Pharmaceutical EVP Matthew Shields Sells Shares

On June 18, 2026, Matthew Shields, Executive Vice President of Global Operations at Teva Pharmaceutical Industries Limited, sold 9,989 shares of the company. The transaction was valued at approximately $321,545.91, with an average price of $32.19 per share. This sale was not part of a pre-arranged trading plan.

Insider Buying and Selling at Teva Pharmaceutical Industries Limited

Matthew Shields' sale is part of recent insider activity at Teva Pharmaceutical. On June 11, Eliyahu Sharon Kalif, EVP and Chief Financial Officer, sold 106,563 shares at an average price of $34.10 under a planned trading program. Earlier in June, Tal Zvi Zaks sold 14,492 shares, while Amir Elstein, Ronit Satchi-Fainaro, and CEO Richard Francis each bought 14,492 shares on June 5.

Other Institutional Activity in Teva Pharmaceutical

Major institutional investors have been adjusting their positions in Teva Pharmaceutical. BlackRock, Inc. increased its holdings by 6,833,776 shares, ending with 65,136,464 shares valued at about $1.96 billion, marking an 11.7% increase. Harel Insurance Investments & Financial Services Ltd. added 1,004,941 shares, bringing its total to 45,956,714 shares worth approximately $1.38 billion, a 2.2% increase. Phoenix Financial Ltd. grew its position by 1,690,283 shares, reaching 42,777,414 shares valued at $1.29 billion, a 4.1% increase. WCM Investment Management, LLC significantly boosted its holdings by 26,813,522 shares, totaling 40,820,600 shares worth $1.16 billion, a 191.4% increase. Menora Mivtachim Holdings Ltd. added 310,200 shares, holding 39,626,383 shares valued at $1.19 billion, a 0.8% increase.

Teva Pharmaceutical Industries Limited Stock Down 11.6%

Shares of NYSE:TEVA traded near $32.20 on Tuesday. The company has a market capitalization of approximately $36.66 billion and a price-to-earnings (P/E) ratio of 23.49. Its forward P/E is 10.17, with a beta of 0.851, indicating lower volatility compared to the market. The stock has traded between $14.99 and $37.35 over the past year, with a 50-day moving average of $33.63 and a 200-day moving average of $28.76. Teva's current ratio stands at 1.013, with a quick ratio of 0.527 and a debt-to-equity ratio of 205.6.

Analysts Set New Price Targets

Analysts have maintained a strong buy rating for Teva Pharmaceutical. On May 6, 2026, Barclays maintained its buy rating with a price target of $40.00. JP Morgan and UBS also maintained their buy ratings with targets of $40.00 and $42.00, respectively, on April 30. Piper Sandler reiterated a buy rating, setting a target of $42.00. Truist Securities maintained a buy rating with a $45.00 target. The consensus among 10 analysts is a strong buy, with a mean target price of $40.90.

About Teva Pharmaceutical

Teva Pharmaceutical Industries Limited is a global leader in the healthcare sector, specializing in the development, manufacturing, and distribution of generic and specialty medicines. Headquartered in Tel Aviv-Yafo, Israel, the company operates in the U.S., Europe, and internationally, focusing on areas like the central nervous system, respiratory, and oncology. Under CEO Richard D. Francis, Teva employs over 31,000 people. The company offers a wide range of products, including tablets, injectables, and inhalants, along with active pharmaceutical ingredients and contract manufacturing services.

Bottom Line

Matthew Shields' recent sale of shares in Teva Pharmaceutical highlights ongoing insider activity at the company. Investors often track insider transactions for potential insights into a company's prospects, though such sales do not necessarily indicate negative sentiment. Teva remains a significant player in the pharmaceutical industry, with strong institutional support and a positive analyst outlook. Keep in mind that insider transactions and analyst ratings are just one piece of the puzzle when assessing a company's stock.